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Abstract 
This presentation is a brief review of current knowledge concerning some biochemical, physiological and medical aspects of the 
function of ubiquinone (coenzyme Q) in mammalian organisms. In addition to its well-established function as a component of the 
mitochondrial respiratory chain, ubiquinone has in recent years acquired increasing attention with regard to its function in the reduced 
form (ubiquinol) as an antioxidant. Ubiquinone, partly in the reduced form, occurs in all cellular membranes a  well as in blood serum 
and in serum lipoproteins. Ubiquinol efficiently protects membrane phospholipids and serum low-density lipoprotein from lipid 
peroxidation, and, as recent data indicate, also mitochondrial membrane proteins and DNA from free-radical induced oxidative damage. 
These effects of ubiquinol are independent of those of exogenous antioxidants, uch as vitamin E, although ubiquinol can also potentiate 
the effect of vitamin E by regenerating it from its oxidized form. Tissue ubiquinone levels are regulated through the mevalonate pathway, 
increasing upon various forms of oxidative stress, and decreasing during aging. Drugs inhibiting cholesterol biosynthesis via the 
mevalonate pathway may inhibit or stimulate ubiquinone biosynthesis, depending on their site of action. Administration of ubiquinone as 
a dietary supplement seems to lead primarily to increased serum levels, which may account for most of the reported beneficial effects of 
ubiquinone intake in various instances of experimental nd clinical medicine. 
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1. Introduction 
Ubiquinone, under the name coenzyme Q, was put on 
the metabolic map by Crane et al. [1] in 1957. It was 
proposed to be a component of the mitochondrial respira- 
tory chain, mediating electron transport between NADH 
and succinate dehydrogenases and the cytochrome system. 
Its structure was determined by Folkers and his colleagues 
[2] in 1958, and was found to be identical to that of a 
quinone earlier described by Morton and associates [3] and 
called by them ubiquinone, with reference to its ubiquitous 
occurrence in various tissues (Fig. 1). Ubiquinone became 
the ~official' name of the compound, established in 1975 
by the IUPAC-1UB Commission on Biochemical Nomen- 
clature [4]. Recently, the term 'vitamin Q' has also been 
proposed [5], with reference to various beneficial effects of 
ubiquinone administered as a dietary supplement. How- 
ever, the name ubiquinone seems to be the most adequate 
name for several reasons: first, it is now clear that 
ubiquinone serves not only as a coenzyme but also, in its 
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reduced form, as an antioxidant; second, it is synthesized 
de noL'o in all animal tissues and cannot thus be regarded 
as a bona fide vitamin; and third, the term ubiquinone 
refers to the quinonoid nature of the compound. This 
makes it simple to refer to its half-reduced and fully 
reduced forms, ubisemiquinone and ubiquinol, which are 
of relevance to its function both in the respiratory chain 
and as an antioxidant. Both of these modes of ubiquinone 
action play an important role in the context of the present 
Symposium. The purpose of this presentation is to discuss 
current knowledge concerning some biochemical, physio- 
logical and medical aspects of ubiquinone in mitochondrial 
function and dysfunction. 
2. Biochemical aspects 
2.1. Role in mitochondrial electron transport 
Although the involvement of ubiquinone as an electron 
carrier between the NADH and succinate dehydrogenases 
and the cytochrome system, proposed by Crane et al. [I] in 
1957. was supported by early evidence obtained in the 
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Fig. 1. Structure of ubiquinone. The number of isoprene units, n, varies 
between 6 and 10 in different species. It is predominantly 10 in human 
and 9 in rat. 
same laboratory with ubiquinone-depleted and 
ubiquinone-replenished submitochondrial particles [6], it 
was not until the end of the 1960s that its function as a 
component of the respiratory chain was generally accepted. 
Doubts concerning this conclusion were mainly based on 
two reasons [7]: (a) the relatively large amounts of 
ubiquinone needed to restore respiration i  ubiquinone-de- 
pleted preparations; and (b) the estimated slow redox 
turnover of endogenous Q as compared to other compo- 
nents of the mitochondrial e ectron-transport system. How- 
ever, these problems were eliminated by (a) the demonstra- 
tion that respiration in ubiquinone-depleted submito- 
chondrial particles using both NADH and succinate as 
substrate could be fully restored after the reincorporation 
of an amount of ubiquinone similar to that originally 
present in the particles [8,9]; and (b) re-evaluation of the 
kinetic data concerning the redox turnover of Q, taking 
into account he fact that ubiquinone is present in mito- 
chondria in molar amounts greatly exceeding those of 
other respiratory-chain carriers [10,1l]. The latter results 
led to the development of the concept of the pool function 
of ubiquinone as a redox carrier between flavin dehydro- 
genases and the cytochrome system [10]. 
From the late 1960s it became evident [12-14] that 
during mitochondrial electron transport ubiquinone also 
occurs as the semiquinone, in addition to the fully oxidized 
and fully reduced states. In 1975-76 Mitchell [15,16] 
developed the concept of 'protonmotive Q cycle' (Fig. 2), 
which involves ubisemiquinone and which accounts for the 
energy conservation occurring at coupling site 2 of the 
respiratory chain. The ubisemiquinone involved in the Q 
cycle was subsequently shown in King's laboratory [17] to 
be stabilized by special ubiquinone-binding proteins. Even 
though the yield of ATP synthesis - -  one or one-half 
molecule of ATP formed per two electrons transferred 
through this particular coupling site - -  is still a matter of 
some uncertainty [18], the protonmotive Q cycle is gener- 
ally accepted as the underlying mechanism [19]. 
2.2. Pro- and antioxidant roles of ubiquinone 
The discovery of the semiquinone form of ubiquinone 
in electron transport raised the question as to a possible 
role of this component in the generation of the superoxide 
radical in the course of mitochondrial respiration [20]. At 
the same time evidence was reported by several aborato- 
ries indicating that the fully reduced form of ubiquinone, 
i.e., ubiquinol, may function as an antioxidant (see Refs. 
[21-27] for reviews). A protective ffect of ubiquinol 
against lipid peroxidation was found with fatty acid emul- 
sions [28,29], mitochondria [30], and submitochondrial p r- 
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Fig. 2. Schematic representation f the mitochondrial respiratory chain ((top) and the protonmotive Q cycle (bottom). 
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ticles [31-33]. In studies of NADH- or NADPH- and 
ADP-Fe3+-induced lipid peroxidation in beef heart sub- 
mitochondrial particles, Takeshige and associates [31-33] 
found that reduction of the endogenous ubiquinone in the 
particles by succinate or NADH resulted in a virtually 
complete inhibition of lipid peroxidation. This protective 
effect was abolished upon removal of the bulk of 
ubiquinone from the particles by lyophilization and pen- 
tane extraction, using a procedure arlier described in our 
laboratory [8,9]. Quantitative r incorporation f ubiquinone 
into the particles by the same procedure [8,9] restored the 
ability of succinate or NADH to inhibit lipid peroxidation 
[32,33]. NADPH was inefficient in reducing ubiquinone 
[33], which, as recent data indicate [34], may be due to a 
bypass of the antimycin-sensitive site of the respiratory 
chain. 
The above studies were meanwhile xtended [35,36] by 
using ascorbate and ADP-Fe 3+ to induce lipid peroxida- 
tion, and succinate or NADH in the presence of antimycin 
to reduce ubiquinone in the submitochondrial particles. It 
was found that the pentane-extraction method used in these 
experiments also removed E vitamin from the particles 
[35,36] and, thus, that the restoration of the inhibition of 
lipid peroxidation upon the reincorporation f ubiquinone 
did not require the presence of vitamin E. These findings 
eliminated an earlier proposal [37] that the antioxidant 
effect of ubiquinol requires mediation by vitamin E. Also 
conversely, incorporation of vitamin E into the extracted 
particles resulted in an inhibition of lipid peroxidation i  
the absence of ubiquinone, the extent of which was en- 
hanced by increasing ascorbate concentrations [36]. 
Ubiquinone, when incorporated into the extracted particles 
together with vitamin E, promoted the uptake of the latter, 
presumably by increasing membrane fluidity [38]. After 
enzymic reduction to ubiquinol, it also amplified the an- 
tioxidant effect of vitamin E as observed at limiting ascor- 
bate concentrations [36], apparently by regenerating the 
vitamin from the c~-tocopheroxyl radical, in accordance 
with earlier observations [37,39-41]. 
Fig. 3 is a schematic representation f our current view 
concerning the mode of action of ubiquinol as an inhibitor 
of lipid peroxidation and its relationship of that of vitamin 
E. The available information is consistent with the conclu- 
sion that ubiquinol acts primarily by preventing the forma- 
tion of lipid peroxyl radicals (LOO), whereas vitamin E is 
generally believed to exert its effect mainly by quenching 
these radicals (cf, Refs. [42,43]). Ubiquinol may exhibit its 
preventive ffect by reducing the initiating perferryl radi- 
cal [36], with the formation of ubisemiquinone and H202. 
The possibility that ubiquinol may act by quenching L, 
yielding LH, has also been considered [35] but seems 
unlikely in view of the very high rate at which L is known 
to react with 02, giving rise to LOO [44]. In addition, 
ubiquinol may act by eliminating LOO, either directly or 
through the regeneration of vitamin E from the c~- 
tocopheroxyl radical, a process that otherwise must rely on 
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Fig. 3. Possible sites of action of ubiquinol (UQH2) , vitamin E (Vit. 
E-OH), and ascorbate (Asc) on lipid peroxidation. LH, polyunsaturated 
fatty acid moiety of a phospholipid; Fe3+-O~ -, perferryl radical; L, 
carbon-centered fatty acid radical; LOO, lipid peroxyl radical; LOOH, 
lipid hydroperoxide; UQ -, ubisemiquinone; Vit-E-O-, o~-tocopheroxyl 
radical; Asc , ascorbyl radical. (From Ref. [36].) 
access to water-soluble antioxidants such as ascorbate (cf. 
Ref. [451). 
In conclusion, it appears that ubiquinol may prevent 
both the initiation and propagation of lipid peroxidation, 
whereas vitamin E acts exclusively as a chain-breaking 
antioxidant, inhibiting propagation. Indeed, ubiquinol ap- 
pears to be in a particularly favourable position to accom- 
plish both of these functions, partly because of its location 
in the hydrophobic region of the membrane phospholipid 
bilayer, where these reactions take place, and, perhaps 
even more importantly, due to its access to a powerful 
enzymic mechanism, the protonmotive Q cycle (cf. Fig. 2), 
which is capable of regenerating ubiquinol from the ubi- 
semiquinone radical. 
Until recently, most in vitro studies of the antioxidant 
effect of ubiquinol were performed with lipid peroxidation 
as the parameter investigated. However, it is well estab- 
lished that oxidative damage in biological systems can also 
occur in other molecular species, in particular protein and 
DNA. It has been shown that protein and DNA can 
undergo xidative damage by way of the hydroxyl radical 
(cf. Ref. [46]), without a simultaneous lipid peroxidation. 
However, there are indications that DNA can be attacked 
by lipid peroxyl and alkoxyl radicals [47-49], resulting in 
base oxidations and strand breaks. Oxidative damage dur- 
ing lipid peroxidation may also occur to proteins, espe- 
cially to those associated with membranes [50]. 
In recent experiments, reported in more detail elsewhere 
[51 ], we used isolated rat liver mitochondria, in which lipid 
peroxidation was initiated by the addition of ascorbate and 
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ADP-Fe 3+, and the concomitant oxidation of proteins and 
DNA was followed by measuring protein carbonylation 
(PC) and the formation of 8-hydroxy-deoxyguanosine (8- 
OH-dG), respectively. Protein damage was also tested by 
measuring the 2,4-dinitrophenol-stimulated ATPase activ- 
ity and by SDS-PAGE. Some of the results are illustrated 
in Fig. 4. 
Incubation with ascorbate +ADP-Fe 3+ resulted in a 
substantial protein carbonylation (Fig. 4B) which, just as 
the lipid peroxidation (Fig. 4A), was inhibited by the 
addition of succinate + antimycin, i.e., conditions that gave 
rise to an extensive (> 80%) reduction of ubiquinone. The 
2,4-dinitrophenol-activated ATPase was inhibited in the 
course of lipid peroxidation, and was protected by succi- 
nate+ antimycin (Fig. 4C). As revealed by SDS-PAGE 
several protein components were affected by lipid per- 
oxidation and protected by succinate+ antimycin (not 
shown). The most striking effect was observed with a 
protein of a molecular mass of approx. 30 kilodaltons, 
which probably is identical with the adenine nucleotide 
translocator. This protein has been shown to he particularly 
sensitive to lipid peroxidation [50], which may be related 
to its close association with cardiolipin [52]. 
There was also an increase in the amount of 8-hydroxy- 
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Fig. 4. Evidence for a protective ffect of endogenous ubiquinol against (A) lipid peroxidation, (B) protein oxidation, (C) inactivation of 2.4-dinitro- 
phenol-stimulated ATPase, and (D) DNA oxidation in isolated rat liver mitochondria. Lipid peroxidation was monitored by estimating malondialdehydc 
(MDA) formation, protein oxidation by measuring carbonylation (PC), and DNA oxidation by determining the amount of 8-hydroxydeoxyguanosine 
(8-OH-dG) formed. ATPase activity and 8-OH-dG formation were measured after an incubation period of 60 rain. Lipid peroxidation was initiated by the 
addition of 0.25 mM ascorbate and ADP + Fe 3 ÷ in concentrations of I mM and 0.01 raM, respectively. Reduction of endogenous biquinone was induced 
by the addition of 5 mM succinate + 2 #M antimycin. (For further details, see Ref. [51].) 
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deoxyguanosine (8-OH-dG), which likewise was prevented 
by succinate + antimycin (Fig. 4D). These effects were 
less striking than in the case of protein oxidation, probably 
because of the relatively high level of 8-OH-dG in the 
control: nevertheless, the trend was clear. Preliminary ex- 
periments with DNA strand breaks as a measure of oxida- 
tive DNA damage also showed an increase upon incuba- 
tion of the mitochondria in the presence of ascorbate +
ADP-Fe 3+, and a protection by succinate + antimycin. 
These results support he conclusion that mitochondrial 
ubiquinol provides protection ot only against lipid per- 
oxidation but also against protein and DNA oxidation. An 
important question, subject to further studies, is whether 
the observed oxidative damage to protein and DNA is 
mediated by lipid peroxidation or occurs parallel to the 
latter. 
3. Physiological aspects 
3.1. Biosynthesis and distribution 
In mammalian cells the biosynthesis of ubiquinone 
involves an interplay of two metabolic sequences, which 
are schematically illustrated in Fig. 5. The quinone moiety 
is derived predominantly from tyrosine (in some instances 
from phenylalanine) which is converted through a number 
of steps to 4-hydroxybenzoate. The polyprenyl side chain 
is synthesized from acetyl-CoA through a reaction se- 
quence, commonly referred to as the mevalonate pathway, 
leading to the formation of farnesyl-PP. The latter, after 
conversion to decaprenyl-PP (or in rodents solanesyl-PP) 
condenses with 4-hydroxybenzoic a id to decaprenoyl-(or 
nonaprenoyl)-4-hydroxybenzoate, whichis then converted 
in a number of additional reaction steps to ubiquinone. 
Famesyl-PP also serves as a precursor of cholesterol and 
dolichol. It also serves as the substrate, either directly or 
through geranylgeranyl-PP, for the covalent modification 
of certain proteins by isoprenylation. 
Relatively little is known about the intracellular local- 
ization of the enzymes leading to the synthesis of 4-hy- 
droxybenzoate. Most enzymes of the mevalonate pathway 
seem to have a multilocal intracellular distribution, with 
different implications for the biosynthesis and transport of 
the three categories of lipids under various physiological 
and pathological conditions [53]. It has been shown [54-57] 
that ubiquinone in animal cells occurs, in addition to 
mitochondria, in the endoplasmic reticulum, the Golgi 
apparatus, the lysosomes, the peroxisomes, and the plasma 
membrane (Table 1). According to current evidence [57,58], 
ubiquinone synthesis begins in the endoplasmic reticulum 
and is completed in the Golgi membranes, from where the 
quinone is transported to various other cellular locations. It 
is also discharged, although to a limited extent, across the 
plasma membrane to the blood, where it is bound to serum 
lipoproteins [58]. In contrast o cholesterol, ubiquinone 
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Fig. 5. Reaction pathways of the biosynthesis of ubiquinone, cholesterol and dolicho}. HMG-CoA indicates 3-hydroxy-3-nleth,,l-glutaryl-coenzyme A. and 
PP pyrophosphate. 
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Table 1 
Distribution of ubiquinone in subcellular fractions from rat liver (from 
Ref. [57]) 
Fraction Ubiquinone ( / zg /mg protein) 
Homogenate 0.79 
Golgi vesicles 2.62 
Lysosomes 1.86 
Mitochondria 1.40 
Inner mitochondrial membrane 1.86 
Microsomes 0.15 
Peroxisomes 0.29 
Plasma membrane 0.74 
Supernatant (cytosol) 0.02 
does not seem to be distributed among different issues via 
the circulation. 
In various human and rat tissues ubiquinone is present 
partly in the reduced form [59], with the extent of reduc- 
tion varying from one tissue to another (Table 2). Also in 
blood it seems to occur partly as ubiquinol [60], which is 
consistent with its function as an antioxidant. The mecha- 
nism by which ubiquinone is reduced in membranes other 
than the inner membrane of mitochondria is unclear. One 
possibility is that quinone reductases in various mem- 
branes carry out this function (cf. Ref. [43] for review). 
The microsomal NADH-cytochrome b 5 and NADPH-cyto- 
chrome P-450 reductases, DT-diaphorase [61] and the 
NADH dehydrogenases a sociated with the mitochondrial 
outer membrane [62] and the plasma membrane [63] may 
serve as ubiquinone reductases. Alternatively, it has been 
considered [25,26] that the reduction may take place by 
way of a temporary fusion between different membranes, 
as has been shown by Takeshige et al. [33] to occur 
between ubiquinone-containing liposomes and submito- 
chondrial particles upplemented with succinate. 
As expected, the antioxidant effect of ubiquinol is not 
restricted to mitochondria. For example, it has been re- 
ported that ubiquinol inhibits lipid peroxidation i  isolated 
Table 2 
Distribution and redox state of ubiquinone in human tissues (from Ref. 
[591) 
Tissue Amount Redox state 
( /xg /g  tissue) (% reduced) 
Heart 114.0 61 
Kidney 66.5 75 
Liver 54.9 95 
Muscle 39.7 65 
Pancreas 32.7 100 
Thyroid 24.7 70 
Spleen 24.6 85 
Brain 13.4 23 
Ventricle 11.8 63 
Intestine 11.5 95 
Colon 10.7 87 
Testis 10.5 85 
Lung 7.9 25 
microsomes [23], and that ubiquinone administration pre- 
vents CCI 4- or ethanol-induced lipid peroxidation in vivo 
in both the mitochondrial nd microsomal fractions of liver 
homogenates [64]. 
3.2. Regulation 
There is growing evidence for the existence of a coordi- 
nate regulation of pro- and antioxidant mechanisms ac- 
cording to the prevailing oxidant status of various tissues. 
A number of reports have been published on this subject 
(see Refs. [23-25] for recent reviews) which will only 
briefly be summarized here. Studies on cold-acclimated 
rats [65], rats treated with thyroid hormone [66], and other 
conditions affecting the overall rate of oxidative 
metabolism [67], have revealed alterations of ubiquinone 
concentrations in highly aerobic tissues, the direction of 
change being the same for metabolic rate, and, thus, for 
free radical production, and for tissue ubiquinone content. 
Significantly, the increase in tissue ubiquinone content 
following thyroid hormone treatment occurred after the 
increase in metabolic rate, suggesting that it was an adapta- 
tion to, rather than a cause of, the increased oxidative 
activity [66]. In this context, it is of interest o note that no 
increase in the ubiquinone content of skeletal muscle was 
found in 'Luft's disease' [68], a state of severe hyperme- 
tabolism of non-thyroid origin, with a defect in mitochon- 
drial respiratory control. 
In general, it appears that several instances of oxidative 
tissue injury at both the experimental nd clinical levels - -  
among them various mitochondrial disorders (cf. Ref. [69]) 
- -  may be related to a defect in the coordination between 
enhanced oxidative activity and increased ubiquinone bio- 
synthesis. In fact, there are numerous reports on beneficial 
effects of ubiquinone-10 administration to patients uffer- 
ing from various myo- and neuropathies related to mito- 
chondrial DNA deletion and other types of oxidative tissue 
injury (cf. Refs. [23,24]). 
Evidence for a coordinate regulation between oxidative 
stress and antioxidant capacity can be derived from studies 
of age-related changes in tissue ubiquinone levels. Beyer et 
al. [70] have reported that the ubiquinone contents of 
several tissues of the rat increase after birth, reaching a 
maximum after 18 months after which they decrease with 
advancing age. Similar observations were made by Kal~n 
et al. [71] in human tissues, which showed a maximal evel 
of ubiquinone in most organs at the age of 20 years 
followed by a decline (Table 3). These data indicate an 
intricate interplay among the three major biosynthetic 
products of mevalonate metabolism, i.e. ubiquinone, 
dolichol and cholesterol. Parallel to the decrease in 
ubiquinone upon aging there is a drastic increase in dolichol 
- -  in certain organs more than 100-fold - -  while the 
cholesterol levels are relatively unchanged. 
Relatively little is known about he mechanism involved 
in the biodegradation of ubiquinone. The turnover ate of 
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Table 3 
Age-related changes in the ubiquinone content of human organs (in 
/xg/g wet weight issue) (from Ref. [71]) 
Organ Age group 
1-3 days 0.7-2 years 19-21 years 39-41 years 77-81 years 
Heart 36.7 78.5 110.0 75.0 47.2 
Kidney 17.4 53.4 98.0 71.1 64.0 
Liver 12.9 45.1 61.2 58.3 50.8 
Pancreas 9.2 38.2 21.0 19.3 6.5 
Spleen 20.7 30.2 32.8 28.6 13.1 
Lung 2.2 6.4 6.0 6.5 3.1 
Adrenal 17.5 57.9 16.1 12.2 8.5 
ubiquinone in various tissues is rather similar, ranging 
between 50 and 125 hours [72]; this is in sharp contrast o 
cholesterol and dolichol turnovers, which are several or- 
ders of magnitude higher in the liver than in the brain [73] 
(Table 4). 
The decrease in ubiquinone content upon increasing age 
is consistent with the 'free radical theory of aging' [74], as 
reflected by an inverse correlation between longevity and 
peroxide-producing potential in mammalian tissues [75]. It 
may also account for the age-related increase in the extent 
of oxidative damage to proteins [76] and DNA [77,78] - -  
the latter especially to mitochondrial DNA - -  as well as 
for the increased incidence of degenerative diseases such 
as cancer [78] and cardiovascular diseases [79]. It appears 
that aging and age-related egenerative diseases may be 
related to a diminished capacity of the organisms to main- 
tain adequate ubiquinol levels in relation to the prevailing 
need for antioxidant defence. 
4. Medical aspects 
4.1. Ubiquinone levels in d&ease 
During the last two decades there has been an increas- 
ing number of publications concerning changes in tissue 
ubiquinone levels in various pathological conditions. In- 
crease in ubiquinone concentration was found in neurode- 
generative conditions of the brain, such as Alzheimer's 
disease in humans [80], prion disease in mice [81] and in 
hyperplastic liver nodules in rats [82]. 
Table 4 
Half-lives of lipids in rat tissues (from Refs. [72] and [73]) 
Tissue Ubiquinone (h) Cholesterol (h) Dolichol (h) 
Thyroid 49 
Muscle 50 
Heart 59 
Stomach 72 
Liver 79 
Brain 90 
Pancreas 94 
Kidney 125 
141 100 
4080 1010 
Decreased ubiquinone levels have been reported in 
several diseases including cardiomyopathies [83], degener- 
ative muscle diseases [84] and hepatocellular carcinomas 
[85]. Whether these changes are the causes or the effects of 
the diseased state is not yet clearly established. It is also 
not yet clear whether and to what extent hese diseases are 
related to an alteration of the bioenergetic capacity and/or  
of the antioxidant status of the tissues concerned. 
4.2. Drug-induced changes 
According to reports from two laboratories [86,87] 
ubiquinol-10 protects human low-density lipoprotein (LDL) 
from lipid peroxidation more efficiently than does c~- 
tocopherol. Dietary supplementation of humans with 
ubiquinone-10 has been shown to result in increased levels 
of ubiquinol-10 within circulating lipoproteins and in- 
creased resistance of LDL to the initiation of lipid per- 
oxidation [88]. Significantly increased LDL/ubiquinone 
ratios are found in patients suffering from ischemic heart 
disease [89] which is not altered by treatment with the 
HMG-CoA reductase inhibitor pravastatin [90]. A similar 
increase is found in familial hypercholesterolemia which 
again is unaffected by pravastatin treatment [91]. 
In general, much interest is currently being focused on 
the effect of various HMG-CoA reductase inhibitors - -  
pravastatin, lovastatin (meviolin) and related anticholes- 
terolemic drugs - -  on tissue ubiquinone levels in vivo. 
The picture that emerges is that these drugs may reduce 
ubiquinone levels to various extent depending on the test 
conditions used [92-95]. An important future aspect of 
these studies would be to investigate the effects of these 
drugs under conditions when the organism is exposed to 
oxidative stress - -  e.g. by physical training - -  and thereby 
to an increased need for ubiquinone synthesis, or during 
aging, when the tissue ubiquinone level and thereby the 
antioxidant capacity, decrease. 
An interesting new development in this field is the use 
of squalestatin 1 as an inhibitor of cholesterol synthesis. 
This fungal product is a potent and specific inhibitor of 
squalene synthetase, i.e. an enzyme that is below the 
branching point of the mevalonate pathway. It inhibits 
cholesterol synthesis electively [96], without affecting the 
synthesis of ubiquinone and dolichol [97]. Moreover, it 
was found that it even enhances ubiquinone synthesis 3- to 
4-fold (Table 5). 
Table 5 
Effect of squalestatin 1 on the relative rates of incorporation of
[3Hlmevalonate into cholesterol, dolichol and ubiquinone in cultures of 
Chinese hamster ovary cells (from Ref. [97]) 
Squalestatin Cholesterol Dolichol Ubiquinone 
1 (mM) (% of control 
0.5 38 118 286 
1.0 8 100 387 
2.0 1.5 86 345 
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Table 6 
Effect of peroxisome proliferators on tissue ubiquinone levels (from Ref. 
[98.]) 
Treatment Tissue Ubiquinone-9 content (% of control) 
3-week treatment 6-week treatment 
Clofibrate 
Di(2-ethylhexyl)phthalate 
liver 131 230 
muscle 112 134 
blood 106 126 
heart 119 135 
brain 107 107 
liver 267 479 
muscle 145 179 
blood l 15 123 
heart 111 121 
brain 100 100 
The peroxisome proliferators clofibrate and di(2-ethyl- 
hexyl)phthalate were recently shown by ,&berg et al. [98] 
to lead to increased ubiquinone levels in the liver, heart 
and skeletal muscle of the rat (Table 6). These effects may 
be attributed to the massive production of hydrogen perox- 
ide caused by these drugs, and thereby a need for enhanced 
antioxidant capacity. 
4.3. Effect of exogenous ubiquinone 
A final point of interest in the present context concerns 
the uptake and distribution of orally administered 
ubiquinone, which has been widely used over the last 20 
years as a prophylax and therapy of a great variety of 
diseases. There is convincing evidence from a number of 
sources (see e.g. Refs. [88,99]) that administration of 
ubiquinone to humans gives rise to an increase in the 
blood level of the quinone (partly present as the quinol), 
and the same is true for the rat [60] (Table 7). Very little is 
known about the uptake of ubiquinone in various human 
organs. In the rat, there is a substantial uptake in the liver 
[100], but this, as recently shown [60], is mainly se- 
questered in the lysosomes. 
The picture that emerges uggests that dietary supple- 
ment of ubiquinone may act primarily by elevating the 
Table 7 
Changes in tissue levels of ubiquinone-10 in various rat tissues upon 
gastric intubation 
Tissue Uptake 
control total 6 hours total 4 days total 8 days 
oxidized reduced 
Blood ~' 0.04 1.02 1.27 0.76 0.85 
Liver h 31 49 165 36 186 
Heart b 22 23 25 22 2 
Kidney b 28 29 30 19 10 
Rats were administered 120 mmol ubiquinone-10 by gastric intubation. 
Ubiquinone-9 levels remained unchanged. For further details see Ref [60]. 
a/.1. mol/1. 
b nmol/g tissuc. 
ubiquinone level in blood, where it may serve several 
important functions. Among these are an enhanced protec- 
tion of LDL from oxidation, a prevention of free-radical 
damage caused by neutrophils in inflammatory diseases, 
and a prevention of oxidative injury by endothelial cells 
resulting from ischemia-reperfusion. These and possibly 
other protective functions against free-radical damage tak- 
ing place in the circulation may account for the majority of 
the reported beneficial effects of ubiquinone adminstration 
in experimental nd clinical medicine. 
5. Conclusions 
Ubiquinone (coenzyme Q), in addition to its function as 
an electron and proton carrier in mitochondrial nd bacte- 
rial electron transport coupled to ATP synthesis, acts in its 
reduced form (ubiquinol) as an antioxidant, inhibiting of 
lipid peroxidation i  biological membranes and in serum 
low-density lipoprotein (LDL). According to recent evi- 
dence it can also protect mitochondrial inner-membrane 
proteins and DNA against oxidative damage accompany- 
ing lipid peroxidation. 
Ubiquinol does not require the mediation of vitamin E 
for its antioxidant activity. However, it can regenerate he 
vitamin from its oxidized form, a process that otherwise 
must rely on water-soluble antioxidants such as ascorbate. 
Ubiquinol is the only known lipid-soluble antioxidant that 
animal cells can synthesize de nouo, and for which there 
exist enzymic mechanisms which can regenerate it from its 
oxidized product formed in the course of its antioxidant 
function. 
Tissue ubiquinone levels are subject to regulation by 
physiological factors that are related to the oxidative activ- 
ity of the organism; they increase under the influence of 
oxidative stress, e.g. physical exercise, cold adaptation, 
thyroid hormone treatment, and decrease during aging. 
Ubiquinone biosynthesis also stimulated by peroxisome 
proliferators, uch as clofibrate and phthalate, probably in 
response to the increased hydrogen peroxide formation 
induced by these agents. Drugs inhibiting cholesterol bio- 
synthesis through the mevalonate pathway may inhibit or 
stimulate the synthesis of ubiquinone, depending on their 
site and mode of action. 
Dietary ubiquinone, i.e., ubiquinone present in food or 
taken as a dietary supplement, seems to act primarily by 
elevating the ubiquinone level in blood, and may there 
serve several important functions such as an enhanced 
protection of LDL from lipid peroxidation, a prevention of 
free-radical damage caused by neutrophils in inflammatory 
diseases, and a prevention of oxidative injury by endothe- 
lial cells resulting from ischemia-reperfusion. These and 
possibly other protective functions against free-radical 
damage taking place in the circulation may account br the 
majority of the reported beneficial effects of ubiquinone 
administration i experimental nd clinical medicine. 
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